List of Excipients in Branded Drug CLINDAMYCIN PHOSPHATE AND TRETINOIN

« Back to Dashboard

Generic Drugs Containing CLINDAMYCIN PHOSPHATE AND TRETINOIN

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	clindamycin phosphate and tretinoin	0472-1790	ANHYDROUS CITRIC ACID
Actavis Pharma Inc	clindamycin phosphate and tretinoin	0472-1790	BUTYLATED HYDROXYTOLUENE
Actavis Pharma Inc	clindamycin phosphate and tretinoin	0472-1790	EDETATE DISODIUM
Actavis Pharma Inc	clindamycin phosphate and tretinoin	0472-1790	GLYCERIN

What are the Most Frequently-Used Excipients in CLINDAMYCIN PHOSPHATE AND TRETINOIN?

# Of NDCs	Excipient
1	ANHYDROUS CITRIC ACID
1	BUTYLATED HYDROXYTOLUENE
1	EDETATE DISODIUM
1	GLYCERIN

Clindamycin Phosphate and Tretinoin Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Clindamycin phosphate and tretinoin is a topical acne combination with an established clinical and regulatory profile. The commercial reference products, Ziana and Veltin, use a gel platform containing clindamycin phosphate equivalent to 1.2% clindamycin and tretinoin 0.025%.[1][2] The main development opportunity is not new molecular protection. It is a differentiated vehicle that improves tolerability, chemical stability, application experience, packaging, adherence, or access.

The strongest opportunities are:

• low-irritation formulations for acne patients sensitive to tretinoin;
• alcohol-reduced or alcohol-free gels;
• improved tretinoin photostability and oxidation control;
• polymer systems with better spreadability and lower tack;
• preservative-optimized or preservative-free packaging;
• lower-cost generic products with robust stability;
• combination products positioned against separate clindamycin and tretinoin prescriptions;
• contract-manufacturing and private-label opportunities for dermatology channels.

What is clindamycin phosphate and tretinoin used for?

Clindamycin phosphate and tretinoin is a topical prescription treatment for acne vulgaris. Clindamycin suppresses Cutibacterium acnes and reduces inflammatory activity. Tretinoin normalizes follicular keratinization and promotes comedolysis.[1][2]

The usual approved combination contains:

Component	Typical strength	Function
Clindamycin phosphate	1.2%, equivalent to 1% clindamycin	Topical antibiotic
Tretinoin	0.025%	Topical retinoid
Dosage form	Gel	Vehicle and delivery system
Administration	Once daily	Patient-use regimen
Indication	Acne vulgaris	Primarily facial acne

The product is intended for external use. Tretinoin can cause erythema, peeling, dryness and burning, while clindamycin can cause irritation and, rarely, antibiotic-associated colitis.[1] A formulation that lowers local irritation without reducing delivery could have greater commercial value than a formulation that only changes inactive ingredients.

What excipients are used in Ziana and Veltin?

The reference formulations use a water-based gel system built around a carbomer polymer. FDA labeling identifies carbomer 934P, methylparaben, polysorbate 80, propylene glycol, purified water and pH-adjusting agents among the inactive ingredients for Ziana.[1] Veltin uses a comparable gel architecture with clindamycin phosphate and tretinoin as the active ingredients.[2]

Reference excipient functions

Excipient category	Representative material	Commercial purpose
Gelling polymer	Carbomer 934P	Viscosity, suspension, residence time
Humectant and solvent	Propylene glycol	Wetting, solvent capacity, skin feel
Surfactant	Polysorbate 80	Wetting and dispersion of tretinoin
Preservative	Methylparaben	Microbial protection
Vehicle	Purified water	Continuous phase
Neutralizer	Sodium hydroxide or comparable base	Carbomer activation and pH adjustment

The excipient strategy must accommodate two chemically different actives. Clindamycin phosphate is water-soluble and ionic. Tretinoin is highly lipophilic, poorly water-soluble and sensitive to light and oxidation. The formulation therefore needs a stable dispersed phase for tretinoin while maintaining clindamycin solubility and acceptable skin delivery.

Which excipient properties matter most for this combination?

Tretinoin solubilization and dispersion

Tretinoin is the primary formulation challenge. Complete molecular solubilization is difficult in a conventional aqueous gel. The developer must control:

• particle size and distribution;
• wetting of tretinoin;
• crystal growth during storage;
• photodegradation;
• oxidation;
• uniformity from first dose to last dose.

Polysorbate 80 can improve wetting and dispersion, but surfactant concentration affects irritation, viscosity and physical stability. Excess surfactant can increase skin discomfort or destabilize the polymer network.

Potential alternatives include nonionic surfactants, amphiphilic solubilizers, lipid-based dispersions, microemulsions and polymeric solubilization systems. Each alternative increases development and regulatory complexity. A simple excipient change is commercially attractive only if it produces a measurable benefit in stability, tolerability or manufacturability.

Carbomer selection and neutralization

Carbomer controls viscosity, yield stress and application behavior. Higher viscosity can increase residence time but may produce tack, pilling or poor spreadability. Lower viscosity can improve cosmetic acceptance but may increase run-off and reduce dose uniformity.

The neutralization process affects:

• final viscosity;
• pH;
• polymer hydration;
• active uniformity;
• preservative performance;
• filling behavior;
• tube or pump compatibility.

A formulation with comparable viscosity but lower yield stress may spread more easily and reduce rubbing-related irritation. A polymer blend can also create a smoother sensory profile than carbomer alone, although the blend must be supported by compatibility and stability data.

Humectants and skin feel

Propylene glycol contributes solvent capacity and water retention. It can also increase stinging in sensitive skin. Development teams may evaluate glycerin, pentylene glycol, propanediol or mixed-humectant systems.

The commercial objective is not simply to replace propylene glycol. It is to balance hydration against:

• tackiness;
• drying time;
• sting;
• tretinoin dispersion;
• preservative efficacy;
• package compatibility.

A low-sting vehicle can be differentiated for patients who discontinue retinoids because of irritation.

Preservative selection

Methylparaben is effective in many aqueous topical systems, but preservative strategy can create a market distinction. Options include phenoxyethanol, benzyl alcohol, sorbate systems, benzoate systems and preservative-free single-use or airless packaging.

Preservative changes affect the product’s regulatory profile. They require preservative-effectiveness testing, compatibility studies and evaluation of irritation potential. A preservative-free formulation can justify a premium only if its package materially limits microbial ingress and the product remains commercially practical.

What formulation strategies can improve commercial differentiation?

Low-irritation gel

A low-irritation gel is the most direct opportunity. The formulation can target reduced sting and dryness through:

• lower solvent load;
• alternative humectants;
• controlled tretinoin particle size;
• optimized pH;
• less aggressive surfactant selection;
• polymer systems that reduce rapid drug release;
• improved moisturization without excessive occlusion.

This strategy is commercially relevant because tretinoin irritation is a major barrier to persistence. The product would compete on tolerability and adherence rather than on active ingredients.

Alcohol-free or reduced-alcohol vehicle

Alcohol can improve drying and sensory performance but may increase irritation. An alcohol-free or reduced-alcohol formulation could target adolescents and adults with sensitive or dry skin.

The principal technical risk is maintaining tretinoin dispersion and acceptable drying time without ethanol. Propylene glycol, propanediol, volatile silicones or other solvent systems may compensate, but each can alter skin feel and preservative performance.

Microdispersed tretinoin system

A controlled microdispersion can improve dose uniformity and reduce visible grittiness. The development focus would be:

• narrow particle-size distribution;
• reduced sedimentation;
• minimal crystal growth;
• consistent release;
• improved photostability.

This approach may generate stronger formulation IP than a routine excipient substitution. Patent value would depend on defined particle-size ranges, process controls, stability results and demonstrated clinical or sensory advantages.

Airless pump or metered-dose package

Packaging can address oxidation, light exposure and contamination. An airless pump may reduce repeated air exchange and improve dosing consistency. A metered-dose system may support once-daily use and reduce uncertainty about the amount applied.

The package must be evaluated for:

• adsorption of tretinoin;
• extractables and leachables;
• dose recovery;
• priming and re-priming;
• residual product;
• compatibility with the gel rheology.

A tube remains the lower-cost option. Airless packaging is more suitable for a premium product or a line extension.

Hydrogel, emulgel or lipid-assisted vehicle

An emulgel or lipid-assisted system can improve tretinoin distribution and skin feel. It may also permit lower use of irritating solvents. The tradeoff is greater manufacturing complexity and a more demanding stability program.

These systems may support a differentiated product if they provide evidence of:

• lower irritation;
• comparable or improved acne outcomes;
• improved cosmetic acceptability;
• better photostability;
• consistent release.

Without those advantages, the additional manufacturing cost may not be recoverable in a generic market.

How should a developer select excipients for a generic product?

A generic developer should first reproduce the reference product’s critical quality attributes rather than pursue broad excipient novelty. Key targets include:

Quality attribute	Development implication
Assay and content uniformity	Control tretinoin dispersion and filling
pH	Maintain clindamycin stability and skin tolerability
Viscosity and rheology	Match spreadability and residence time
Particle size	Control tretinoin release and dose uniformity
In vitro release	Establish comparable release behavior
Microbial limits	Validate preservative and manufacturing controls
Photostability	Protect tretinoin during storage and use
Oxidative stability	Limit degradation products
Package performance	Demonstrate dose delivery and compatibility

For an ANDA, excipient changes that materially alter formulation performance can increase the bioequivalence and chemistry, manufacturing and controls burden. A close formulation may be commercially attractive because it reduces development risk. A materially different vehicle may create a new product opportunity but require more clinical, comparative and intellectual-property work.

What FDA regulatory pathway applies to clindamycin phosphate and tretinoin?

The conventional U.S. pathway is an abbreviated new drug application for a generic equivalent to an approved reference product. Ziana was approved by FDA as a prescription topical acne product under NDA 050756.[1]

A differentiated formulation may require a 505(b)(2) application if it relies on the approved active ingredients but introduces a new formulation, delivery system, strength, route, dosing approach or other change that cannot be fully supported through an ANDA.

Regulatory pathway comparison

Product strategy	Likely pathway	Primary commercial advantage
Close generic to reference gel	ANDA	Lower development cost
New low-irritation gel	505(b)(2) or other supported pathway	Differentiation and potential premium
New package with same formulation	ANDA or 505(b)(2), depending on changes	Dosing and stability advantages
New strength or dosing regimen	505(b)(2)	Broader clinical positioning
New topical delivery platform	505(b)(2)	Formulation IP and market exclusivity potential

FDA’s topical-product guidance emphasizes comparative characterization, including product composition, rheology, particle size, polymorphic form, viscosity and in vitro release where relevant.[3] These attributes are central to both generic and differentiated development.

What patents protect clindamycin phosphate and tretinoin products?

The commercially important protection historically centered on the combination formulation and methods of treating acne, rather than new chemical-entity patents for clindamycin or tretinoin. Core U.S. formulation protection associated with Ziana was limited by the early 2020s, and the product now faces generic competition.[1][4]

A current development program should separate four types of protection:

1. Active-ingredient patents. These are generally not the principal barrier because both actives are long-established.
2. Combination-formulation patents. These may cover specific concentrations, excipient ratios, pH ranges, viscosity, particle sizes or stability characteristics.
3. Method-of-use patents. Claims may cover treatment of acne, dosing frequency, patient populations or combination use.
4. Manufacturing and packaging patents. These may protect dispersion methods, low-oxygen filling, airless containers or controlled-dose delivery.

Orange Book status must be assessed against the current FDA publication and product-specific patent listings before launch planning. A developer should not assume that historic Ziana patents still block a new product, nor should it assume that an unlisted formulation patent has no litigation value.[4]

When does clindamycin phosphate and tretinoin lose exclusivity?

The reference product’s regulatory exclusivity and patent protection are substantially exhausted compared with the product’s initial U.S. launch period. Ziana received FDA approval in 2006.[1] Market entry is therefore governed mainly by remaining patents, Orange Book listings, ANDA timing, formulation similarity and commercial execution rather than by active-ingredient exclusivity.

Unlike biologic products, the combination has no biosimilar pathway. It is a small-molecule topical product. The relevant competitive threats are:

• ANDA filers;
• authorized generics;
• 505(b)(2) formulation products;
• physician substitution;
• separate prescriptions for generic clindamycin and generic tretinoin.

What Paragraph IV challenges and litigation affect the product?

Paragraph IV risk is relevant when an ANDA applicant certifies that listed patents are invalid, unenforceable or not infringed. Historic litigation involving Ziana and generic applicants affected the timing of generic entry, but the commercial importance of those disputes has declined as the core product has aged and generic alternatives have become available.[4]

A launch assessment should review:

• current Orange Book patent listings;
• ANDA approvals and tentative approvals;
• Paragraph IV notices;
• 30-month stays;
• litigation settlements;
• authorized-generic arrangements;
• state substitution rules;
• remaining formulation or method patents.

Settlement agreements may include launch dates, licenses, supply terms or restrictions on product design. Publicly disclosed settlements should be examined for any continuing impact on specific formulations, strengths or manufacturers.

How strong is the patent estate for a new excipient platform?

A routine excipient substitution usually has weak patent strength. A stronger estate combines composition, process, package and clinical-performance claims.

Stronger claim architecture

• defined tretinoin particle-size distribution;
• specified polymer and surfactant ratios;
• controlled pH and rheological ranges;
• reduced degradation-product profile;
• photostable package configuration;
• manufacturing process that produces a reproducible dispersion;
• demonstrated reduction in irritation or improved adherence;
• claims directed to a defined patient subgroup.

A patent based only on replacing propylene glycol with another humectant may be vulnerable to obviousness and design-around arguments. A formulation that combines a defined microstructure, stability profile and clinically relevant tolerability result has a stronger commercial position.

Geographic protection should include the United States, European Union, Japan, Canada, Australia and major dermatology markets where topical acne products have substantial volume. Process claims may have limited practical value if manufacturing can occur in a jurisdiction outside the claim scope or if the final product can be made through an alternative process.

What commercial opportunities exist for manufacturers?

Low-cost generic supply

The largest near-term opportunity is efficient generic production. Success depends on:

• low-cost carbomer processing;
• reliable tretinoin dispersion;
• high-yield filling;
• tube or pump compatibility;
• short batch-release timelines;
• strong stability data;
• pharmacy and wholesaler access.

Margins may be pressured by multiple generic suppliers, but manufacturing efficiency and dependable supply can support institutional and dermatology-channel contracts.

Premium dermatology product

A 505(b)(2) product can target patients who discontinue conventional tretinoin because of irritation. Pricing support would require clinical or real-world evidence showing improved tolerability, adherence or outcomes.

Potential claims include:

• lower irritation;
• improved cosmetic acceptability;
• once-daily convenience;
• lower visible residue;
• improved stability;
• controlled dosing.

The product should avoid unsupported superiority claims. A premium vehicle without measurable clinical or user-experience benefit may not justify higher reimbursement.

Private-label and teledermatology

Teledermatology and subscription acne services create demand for standardized combination products, particularly in tubes or metered-dose packages. A manufacturer can offer:

• contract development;
• private-label supply;
• integrated packaging;
• stability support;
• pharmacovigilance services;
• multiple tube sizes.

This model can generate volume without requiring a large consumer advertising budget.

International licensing

Licensing opportunities are strongest where a developer has:

• an approved or near-approved formulation;
• manufacturing capacity;
• a differentiated package;
• regional regulatory expertise;
• patent protection in target markets.

The commercial case is weaker for an undifferentiated generic because local manufacturers may already compete on price.

How does clindamycin phosphate and tretinoin compare with competing acne products?

Product class	Main advantage	Main limitation	Excipient opportunity
Clindamycin/tretinoin combination	Treats inflammatory and comedonal acne in one product	Tretinoin irritation and antibiotic stewardship concerns	Low-irritation, stable, cosmetically acceptable gel
Adapalene/benzoyl peroxide	Strong non-antibiotic combination	Dryness, irritation and bleaching from benzoyl peroxide	Moisturizing and non-bleaching vehicle
Tretinoin monotherapy	Established retinoid therapy	No antibacterial component	Controlled-release or low-irritation delivery
Clindamycin/benzoyl peroxide	Antibacterial and peroxide combination	Dryness, odor and textile bleaching	Odor control and reduced irritation
Azelaic acid products	Antimicrobial and keratinization effects	Slower consumer-perceived results for some users	Improved spreadability and lower residue
Oral or topical antibiotics	Anti-inflammatory and antibacterial activity	Resistance and systemic or local tolerability concerns	Not an excipient-led opportunity

Antibiotic stewardship may limit long-term use of clindamycin-containing products. A commercial strategy should position the product for appropriate, time-limited use and consider combination or maintenance regimens that reduce prolonged antibiotic exposure.[5]

What revenue exposure and launch scenarios should investors model?

Revenue depends on product access, payer substitution, price erosion and the degree of differentiation.

Launch scenario	Product type	Expected commercial profile
Basic generic	Reference-like gel	Fast access, high price pressure
Authorized or preferred generic	Reliable supply with channel access	Better volume and lower discounting
Differentiated generic	Improved package or sensory profile	Moderate premium potential
505(b)(2) low-irritation product	New vehicle with supporting evidence	Higher price, higher development cost
Premium dermatology brand	Clinical and adherence differentiation	Highest price potential, highest marketing burden

The largest risk is commoditization. The largest upside is a demonstrably better-tolerated formulation that wins patients who do not persist with standard tretinoin gels. Investors should value formulation claims, regulatory pathway certainty, manufacturing scalability and payer access more heavily than historic brand sales.

Key Takeaways

• Clindamycin phosphate and tretinoin is a mature topical acne combination based on clindamycin phosphate 1.2% and tretinoin 0.025%.
• The core formulation challenge is dispersing and stabilizing lipophilic, oxidation-sensitive tretinoin while maintaining clindamycin solubility and acceptable skin feel.
• Carbomer, polysorbate, propylene glycol, preservatives and pH adjusters are central to the reference gel architecture.
• The strongest excipient opportunities are low-irritation vehicles, improved tretinoin dispersion, alcohol-reduced systems and controlled-dose packaging.
• Basic generic entry is likely to face price erosion. A differentiated formulation can support a 505(b)(2) strategy and potentially command a premium.
• Patent value is stronger for defined composition, particle-size, stability, process and package claims than for routine excipient substitutions.
• There is no biosimilar risk because the product is a small-molecule topical combination.
• Current Orange Book listings, Paragraph IV activity and settlement terms must control any launch or litigation assessment.
• Antibiotic stewardship and the availability of non-antibiotic acne products are material commercial constraints.

FAQs

Can tretinoin stability be improved without changing the active ingredients?

Yes. Developers can improve stability through particle-size control, oxygen reduction, light-protective packaging, optimized surfactant selection, pH control and manufacturing-process controls.

Is a preservative-free clindamycin phosphate and tretinoin gel commercially attractive?

It can be attractive for sensitive-skin positioning, but it requires a package that limits microbial ingress and a strong preservative-effectiveness or microbial-control strategy. The higher package cost must be supported by a meaningful tolerability or marketing benefit.

Can a new excipient combination obtain patent protection?

Yes, but routine substitutions are generally weaker. Stronger protection requires defined composition ranges, physical attributes, manufacturing steps or demonstrated stability and clinical advantages.

Is a 505(b)(2) application preferable to an ANDA for a new gel?

A 505(b)(2) application is more suitable when the product has a materially different vehicle, package, dosing approach or clinical-use profile. An ANDA is generally more efficient for a close formulation equivalent.

What is the largest unmet formulation need in this product class?

The largest practical opportunity is a tretinoin vehicle that reduces irritation and improves adherence while maintaining chemical stability, dose uniformity, manufacturing simplicity and acceptable cost.

References

1. U.S. Food and Drug Administration. (2006). Ziana gel: Clindamycin phosphate and tretinoin prescribing information. NDA 050756.

2. U.S. Food and Drug Administration. (2010). Veltin gel: Clindamycin phosphate and tretinoin prescribing information. FDA-approved labeling.

3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Acyclovir topical cream, acyclovir topical ointment, and acyclovir topical suspension: Product-specific guidance and topical dermatological drug product development considerations. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Electronic Orange Book. FDA.

5. American Academy of Dermatology Association. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.e33.